loader
Please Wait
Applying Filters...
menu
    • menu

    Digital Content for Nalmefene Hydrochloride

    Client Email Product
    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Bora Pharmaceuticals- Making success more certain.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.

    Virtual Booth

    Contact Supplier

    Axplora- The partner of choice for complex APIs.

    Virtual Booth

    Contact Supplier

    Fareva is a one-stop-shop for API/HPAPI, OSD & Sterile products, is USFDA, EMA and PMDA-inspected and has multiple NDA & ANDA filings.

    Virtual Booth

    Contact Supplier

    Menu

    Nalmefene Hydrochloride

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    REF. STANDARDS & IMPURITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 39,449Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Approves First Nalmefene Hydrochloride Auto-Injector
    FDA Approves First Nalmefene Hydrochloride Auto-Injector

    09 Aug 2024

    // FDA

    https://www.fda.gov/news-events/press-announcements/fda-approves-first-nalmefene-hydrochloride-auto-injector-reverse-opioid-overdose

    FDA
    09 Aug 2024
    Share Share
    FDA Approves Zurnai Auto-Injector For Emergency Opioid Overdose Treatment
    FDA Approves Zurnai Auto-Injector For Emergency Opioid Overdose Treatment

    07 Aug 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240807347421/en

    BUSINESSWIRE
    07 Aug 2024
    Share Share
    FDA Accepts Filing of NDA for Nalmefene for the Treatment of Opioid Overdose
    FDA Accepts Filing of NDA for Nalmefene for the Treatment of Opioid Overdose

    08 Apr 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240408735407/en

    BUSINESSWIRE
    08 Apr 2024
    Share Share
    Purdue Awards Grant for to Examine Opioid Overdose Reversal Using Nalmefene HCl
    Purdue Awards Grant for to Examine Opioid Overdose Reversal Using Nalmefene HCl

    27 Mar 2024

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20240327450490/en

    BUSINESSWIRE
    27 Mar 2024
    Share Share
    Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone
    Indivior Announces Publication Demonstrating that OPVEE® (nalmefene) Nasal Spray Rapidly Reverses Effects of Opioid-Induced Respiratory Depression in Head-to-Head Study Against Intranasal Naloxone

    11 Mar 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/indivior-announces-publication-demonstrating-that-opvee-nalmefene-nasal-spray-rapidly-reverses-effects-of-opioid-induced-respiratory-depression-in-head-to-head-study-against-intranasal-naloxone-302085667.html

    PR NEWSWIRE
    11 Mar 2024
    Share Share
    FDA approves another new type of opioid overdose antidote nasal spray
    FDA approves another new type of opioid overdose antidote nasal spray

    23 May 2023

    // Zachary Brennan ENDPTS

    https://endpts.com/fda-approves-another-new-type-of-opioid-overdose-antidote-nasal-spray/

    Zachary Brennan ENDPTS
    23 May 2023
    Share Share